Coinbase CEO Brian Armstrong’s NewLimit Secures $130M to Revolutionize Age-Reversing Treatments
NewLimit, a pioneering startup focused on extending healthy human lifespan through innovative genetic programming, has successfully secured a substantial $130 million Series B funding round, led by Kleiner Perkins. This investment underscores the company’s commitment to revolutionizing the field of anti-aging medicine.
Funding Details and Investors
The recent funding round attracted several prominent investors, including:
Returning backers such as Founders Fund, Dimension Capital, Elad Gil, Garry Tan, and Patrick Collison also participated in this funding round. This new investment comes two years after NewLimit raised a $40 million Series A.
About NewLimit
Founded over four years ago by Coinbase CEO Brian Armstrong, former GV partner Blake Byers, and stem cell professor Jacob Kimmel, NewLimit is making strides in developing treatments that aim to restore youthful characteristics to aged cells.
Recent Developments in Anti-Aging Science
According to Jacob Kimmel in an interview with TechCrunch, the company has successfully discovered three prototype medicines that reprogram liver cells to regain their youthful functions. These lab experiments indicate that:
- Rejuvenated liver cells can effectively process fats.
- Cells regain the ability to metabolize alcohol.
NewLimit evaluates its progress by comparing the responses of cells from younger individuals to those from older adults. Kimmel emphasizes that an older liver cell undergoing NewLimit’s epigenetic reprogramming reacts similarly to a younger cell.
Future Directions and AI Integration
Despite promising early results, NewLimit is still a few years away from initiating human trials. In the interim, the company aims to enhance its anti-aging treatments using an advanced AI model. This model enables NewLimit to:
- Conduct simulations of various experiments.
- Focus on the most promising drug candidates.
Kimmel explains that the data generated from these experiments helps retrain the AI model in a process known as “lab in a loop,” optimizing future research.
Other Biotech Startups in the Anti-Aging Space
NewLimit is not alone in the race to develop lifespan-extending therapies. Other notable biotech startups include:
- Retro Biosciences – which raised $180 million from OpenAI CEO Sam Altman and is reportedly seeking a $1 billion Series A.
- Altos Labs – launched with a staggering $3 billion in funding backed by Jeff Bezos.
With advancements in genetic programming and artificial intelligence, the future of anti-aging medicine looks promising. For more insights into biotechnology innovations, visit Biotech News.
